| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|---|---|
Revenues | |||||||
- | - | - | - | - | 0 | 0 | - |
Operating expenses: | |||||||
Research and development | |||||||
27,843 | 14,425 | 14,526 | - | - | - | - | - |
Acquired in-process research and development | |||||||
- | - | 63,844 | - | - | - | - | - |
Costs of revenues | |||||||
- | - | - | 5,401 | 2,249 | 0 | 0 | - |
Research and development | |||||||
- | - | - | 21,641 | 18,433 | 21,784 | 15,802 | 6,323 |
Selling, general and administrative | |||||||
- | - | - | 49,223 | 51,594 | 26,149 | 13,332 | 7,206 |
Restructuring | |||||||
- | - | - | 5,400 | 0 | 0 | - | - |
General and administrative | |||||||
17,556 | 8,691 | 5,956 | - | - | - | - | - |
Other general expenses | |||||||
0 | 3,758 | - | - | - | - | - | - |
Total costs and expenses | |||||||
- | - | - | 81,665 | 72,276 | 47,933 | 29,134 | 13,529 |
Loss from operations | |||||||
-45,399 | -26,874 | -84,326 | -81,012 | -71,999 | -47,933 | -29,134 | -13,529 |
Other expenses: | |||||||
Interest expense (income), net | |||||||
1,038 | -134 | - | - | - | - | - | - |
Other loss | |||||||
-207 | -169 | - | - | - | - | - | - |
Interest expense, net | |||||||
- | - | 288 | - | - | - | - | - |
Change in fair value of preferred stock warrant liability | |||||||
- | - | -28 | - | - | - | - | - |
Net loss | |||||||
-44,568 | -27,177 | -84,586 | - | - | - | - | - |
Net (income) loss attributable to noncontrolling interest | |||||||
0 | 15 | -8 | - | - | - | - | - |
Interest income, net | |||||||
- | - | - | - | - | -126 | 90 | - |
Interest (expense) income, net | |||||||
- | - | - | - | - | - | - | 19 |
Other income (expense), net | |||||||
- | - | - | -164 | -20 | 122 | 0 | - |
Loss from equity method investment | |||||||
- | - | - | -1,542 | -1,561 | -1,583 | 0 | - |
Loss before income taxes | |||||||
- | - | - | -82,059 | -73,144 | -49,520 | -29,044 | - |
Income tax expense | |||||||
- | - | - | 201 | 75 | 0 | 0 | - |
Net loss attributable to common stockholders | |||||||
-44,568 | -27,192 | -84,578 | -82,260 | -73,219 | -49,520 | -29,044 | -13,510 |
Net loss per share of common stock, basic and diluted (in USD per share) | |||||||
-3.25 | -17.58 | -321.81 | -2.56 | -2.70 | -2.19 | -1.80 | -2.33 |
Weighted-average shares of common stock outstanding, basic and diluted (in shares) | |||||||
13,706 | 1,547 | 262 | 32,148 | 27,085 | 22,647 | 16,160 | 5,810 |
Other comprehensive income (loss): | |||||||
Foreign currency translation adjustment | |||||||
17 | 140 | 10 | - | - | - | - | - |
Comprehensive loss | |||||||
- | - | -84,568 | - | - | - | - | - |
Comprehensive income attributable to noncontrolling interest | |||||||
- | - | 2 | - | - | - | - | - |
Comprehensive loss attributable to Millendo Therapeutics, Inc. | |||||||
- | - | -84,570 | - | - | - | - | - |
Net loss | |||||||
- | - | - | - | - | -49,520 | -29,044 | -13,510 |
Net loss | |||||||
-44,568 | -27,192 | -84,578 | -82,260 | -73,219 | - | -29,044 | -13,510 |
Unrealized gains on available-for-sale securities | |||||||
- | - | - | 110 | -144 | -36 | 16 | -6 |
Comprehensive loss | |||||||
-44,551 | -27,052 | - | -82,150 | -73,363 | -49,556 | -29,028 | -13,516 |
Stock-based compensation expense | |||||||
- | - | - | - | - | - | - | 1,382 |